(HOTH) Hoth Therapeutics - Ratings and Ratios

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company tackling unmet medical needs through innovative therapies. Their diverse pipeline includes treatments for various conditions, such as skin disorders associated with cancer therapy, mast-cell derived cancers, traumatic brain injury, Alzheimers disease, asthma, allergies, eczema, and lupus.

The companys lead candidate, HT-001, is in Phase II clinical trials, while their BioLexa Platform is in Phase I trials. With multiple license agreements with prestigious institutions, including the George Washington University and the University of Cincinnati, Hoth Therapeutics has established a strong foundation for its research and development efforts.

Analyzing the , we observe a current price of $0.84, with short-term moving averages (SMA20: $0.88, SMA50: $0.91) indicating a potential downward trend. The Average True Range (ATR) of 0.06 (7.20%) suggests moderate volatility. Given the , the companys Market Cap stands at $11.20M, with a negative P/E ratio and a Return on Equity (RoE) of -109.19, indicating significant losses.

Based on the available data, a forecast for HOTH can be constructed. The companys pipeline and license agreements are positives, but the negative financials and downward trend in the stock price are concerns. Assuming successful clinical trials and eventual commercialization of their therapies, a potential price target could be $2.50-$3.50, representing a 200-300% increase from current levels. However, this is contingent upon the company addressing its financial challenges and achieving significant milestones in its clinical trials. The high volatility and current downward trend suggest that investors should exercise caution and closely monitor the companys progress.